High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation

AIM: To investigate the impact of high-dose hepatitis B immunoglobulin(HBIG) on hepatocellular carcinoma(HCC) and hepatitis B virus(HBV) recurrence and overall survival after living donor liver transplantation(LDLT).METHODS: We investigated 168 patients who underwent LDLT due to HCC, and who were HBV-DNA/hepatitis B e antigen(HBe Ag)-positive, from January 2008 to December 2013. After assessing whether the patients met the Milan criteria, they were assigned to the low-dose HBIG group and high-dose HBIG group. Using the propensity score 1:1 matching method, 38 and 18 pairs were defined as adhering to and not adhering to the Milan criteria. For each pair, HCC recurrence, HBV recurrence and overall survival were analyzed by the Kaplan-Meier method and the log rank test according to the HBIG dose. RESULTS: Among those who met the Milan criteria, the 6-mo, 1-year, and 3-year HCC recurrence-free survival rates were 88.9%, 83.2%, and 83.2% in the low-dose HBIG group and 97.2%, 97.2%, and 97.2% in the high-dose HBIG group, respectively(P = 0.042).In contrast, among those who did not meet the Milan criteria, HCC recurrence did not differ according to the HBIG dose(P = 0.937). Moreover, HBV recurrence and overall survival did not differ according to the HBIG dose among those who met(P = 0.317 and 0.190, respectively) and did not meet(P = 0.350 and 0.987, respectively) the Milan criteria. CONCLUSION: High-dose HBIG therapy can reduce HCC recurrence in HBV-DNA/HBe Ag-positive patients after LDLT.

Perioperative remedial antiviral therapy in hepatitis B virus-related hepatocellular carcinoma resection:How to achieve a better outcome

BACKGROUND Although the benefits of antiviral therapy for hepatitis B virus(HBV)-related hepatocellular carcinoma(HCC)have been proven,researchers have not con-firmed the differences in patient outcomes between patients who received preoperative antiviral therapy for a period of time(at least 24 wk)and patients who received remedial antiviral therapy just before radical resection for HBV-related HCC.AIM To investigate the efficacy of perioperative remedial antiviral therapy in patients with HBV-related HCC.METHODS A retrospective study of patients who underwent radical resection for HBV-related HCC at the First Affiliated Hospital of Xi’an Jiaotong University from January 2016 to June 2019 was conducted.Considering the history of antiviral therapy,patients were assigned to remedial antiviral therapy and preoperative antiviral therapy groups.RESULTS Kaplan–Meier analysis revealed significant differences in overall survival(P<0.0001)and disease-free survival(P=0.035)between the two groups.Multivariate analysis demonstrated that a history of preoperative antiviral treatment was independently related to improved survival(hazard ratio=0.27;95%confidence interval:0.08-0.88;P=0.030).CONCLUSION In patients with HBV-related HCC,it is ideal to receive preoperative long-term antiviral therapy,which helps patients tolerate more extensive hepatectomy;however,remedial antiviral therapy,which reduces preoperative HBV-DNA levels to less than 4 Log10 copies DNA/mL,can also result in improved outcomes.

Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments

In this editorial,we discussed the apparent discrepancy between the findings described by Colapietro et al,in their case report and data found in the literature.Colapietro et al reported a case of hepatitis B virus(HBV)-related hepatic decompensation in a patient with chronic myeloid leukemia and a previously resolved HBV infection who was receiving Bruton’s tyrosine kinase(BTK)inhibitor therapy.First of all,we recapitulated the main aspects of the immune system involved in the response to HBV infection in order to underline the role of the innate and adaptive response,focusing our attention on the protective role of anti-HBs.We then carefully analyzed literature data on the risk of HBV reactivation(HBVr)in patients with previous HBV infection who were treated with either tyrosine kinase inhibitors or BTK inhibitors for their hematologic malignancies.Based on literature data,we suggested that several factors may contribute to the different risks of HBVr:The type of hematologic malignancy;the type of therapy(BTK inhibitors,especially second-generation,seem to be at a higher risk of HBVr than those with tyrosine kinase inhibitors);previous exposure to an anti-CD20 as first-line therapy;and ethnicity and HBV genotype.Therefore,the warning regarding HBVr in the specific setting of patients with hematologic malignancies requires further investigation.

Timing of antiviral therapy in patients with hepatitis B virus related hepatocellular carcinoma undergoing hepatectomy

Globally,hepatocellular carcinoma(HCC)is among the most prevalent and deadly cancers.Hepatitis B virus(HBV)infection is an important etiology and disease progression factor for HCC.Hepatectomy is a widely accepted curative treatment for HCC,but the long-term survival rate is still unsatisfactory due to the high recurrence rate after resection.Preoperative or postoperative antiviral therapy plays an important role in improving the prognosis for HBV-related HCC patients who underwent hepatectomy.However,many patients miss out on the chance to receive long-term preoperative antiviral medication because their HBV and HCC infections are discovered concurrently,necessitating the start of remedial antiviral therapy in the perioperative phase.Therefore,it is of great value to know when antiviral therapy is more appropriate and whether perioperative rescue antiviral therapy can achieve the effect of preoperative long-term antiviral therapy.

病毒感染与氧化应激的关系

病毒感染和氧化损伤密切相关。病毒感染可引起机体广泛的氧化应激反应,并进一步加重疾病。本文针对RNA、DNA及逆转录病毒,尤其侧重于流感病毒、乙肝病毒和人免疫缺陷病毒,从病毒感染诱导产生活性氧自由基(reactive oxygen species,ROS)的能力、病毒与ROS的相互影响、病毒在机体氧化/抗氧化平衡中发挥的作用、抗氧化剂在病毒感染中的治疗作用等方面对病毒感染和氧化应激的关系作一综述。

口蹄疫病毒重组鸡痘病毒活载体疫苗和DNA疫苗免疫牛的试验研究

将本课题组构建的共表达FMDV衣壳蛋白前体P1-2A基因以及蛋白酶3C基因的重组鸡痘病毒活载体疫苗vUTAL3CP1以及共表达P1-2A和猪白介素18基因的重组DNA疫苗(pVIRIL18P1),分别以单独及混合的共3种方式接种牛,然后通过间接ELISA、中和试验和T淋巴细胞增殖试验评价其诱导的特异性体液和细胞免疫水平。结果表明这2种基因工程疫苗均能诱导牛产生特异性的体液及细胞免疫应答。其中重组鸡痘病毒vUTAL3CP1免疫组以及联合免疫组(vUTAL3CP1/pVIRIL18P1,pVIRIL18P1/vUTAL3CP1)诱导的中和抗体滴度分别达到1∶64、1∶64和1∶54,已接近于常规灭活疫苗水平(1∶90),而特异性的T淋巴细胞增殖反应则比后者高得多(P<0.01)。该研究结果为进一步进行免疫攻毒试验,并最终筛选出最佳疫苗和免疫程序奠定了基础。

vUTAL3CP1重组载体疫苗与pVIRIL18P1 DNA疫苗在猪体内的免疫原性研究

目的评价本课题组构建的共表达FMDV衣壳蛋白前体P1-2A基因以及免疫辅助基因的重组鸡痘病毒vUTAL3CP1和重组DNA疫苗pVIRIL18P1在猪体内诱导特异性体液免疫和细胞免疫的能力。方法将上述2种疫苗采用4种不同的组合方式单独或联合给猪进行肌肉注射,用ELISA方法和中和实验检测猪产生的抗体水平,T淋巴细胞增殖反应、CTL反应以及T淋巴细胞亚类。结果这2种基因工程疫苗均能诱导猪产生特异性的体液及细胞免疫应答。其中单独免疫组vUTAL3CP1/vUTAL3CP1的效果最好,其诱导的抗体水平已接近于常规灭活疫苗,而细胞免疫水平则比后者高得多。联合免疫组中vUTAL3CP1/pVIRIL18P1可以诱导比vUTAL3CP1/vUTAL3CP1更高的CTL杀伤活性,但体液免疫水平略低。结论证实了这2种基因工程疫苗在猪体内均有良好的免疫原性。同时初步筛选出vUTAL3CP1/vUTAL3CP1和pVIRIL18P1/vUTAL3CP1组等较佳的免疫策略,为下一步的攻毒保护试验奠定了基础。

牛对表达口蹄疫病毒复合多表位基因的重组鸡痘病毒以及DNA疫苗联合免疫的免疫应答

将构建的共表达口蹄疫病毒(foot-and-mouth disease virus,FMDV)复合多表位基因和猪白细胞介素18基因的重组鸡痘病毒活载体疫苗vUTA2-OAT以及DNA疫苗pVRI-OAT,分别以vUTA2-OAT/vVTA2-OAT(首免/加强免疫)、pVRI-OAT/vUTA2-OAT(首免/加强免疫)和vUTA2-OAT/pVRI-OAT(首免/加强免疫)等3种方式接种牛,然后通过间接ELISA、中和试验和T淋巴细胞增殖试验评价其诱导的特异性体液和细胞免疫水平。结果表明,这3种方式均能诱导牛产生特异性的体液免疫及细胞免疫应答,其中pVRI-OAT/vUTA2-OAT联合免疫方式的免疫效果最佳,诱导的中和抗体达1∶64,已接近于常规灭活疫苗免疫方式,而且其可以诱导比灭活疫苗免疫方式高得多的细胞免疫水平(P<0.01)。上述试验结果为进一步进行免疫攻毒试验,并最终筛选出最佳疫苗和免疫程序奠定了基础。

HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection

Molecular virology methods including polymerase chain reaction, cloning and sequencing have revolutionised our understanding of viral genome variation. In the case of hepatitis B virus (HBV), sequencing studies have identified a number of virus variants normally found during the natural course of chronic infection. The appearance of the precore stop codon (with G-for-A substitution at position 1896) and basal core promoter (BCP) (with A-for-T and G-for-A, at positions 1762 and 1764, respectively) variants which reduce or abrogate hepatitis B e antigen (HBeAg) production, heralds the initiation of the seroconversion phase from HBeAg to anti-HBe positivity. The gradual removal of the tolerogenic effect of HBeAg leads to the awakening of the immune response (immune clearance phase). Most patients after HBeAg seroconversion become &#x0201c;inactive HBsAg carriers&#x0201d;. However during the course of infection precore and/or BCP variants may emerge and be selected leading to HBeAg negative chronic hepatitis B (CHB) with high viremia levels (reactivation phase). The prevalence of HBeAg negative CHB has been increasing over the last few decades and has become the commonest type of HBV infection in many countries of the world. This probably reflects the aging of existing HBV carriers and the effective prevention measures restricting new HBV infections. Frequent acute exacerbations accompanied by high viral replication, elevated alanine aminotransferase levels and histological activity are a common feature of HBeAg negative CHB leading to cirrhosis much faster than in HBeAg positive CHB patients.

表达口蹄疫病毒复合多表位基因的重组鸡痘病毒以及DNA疫苗在豚鼠中的免疫原性研究

目的评价本课题组构建的共表达FMDV复合多表位基因以及猪白细胞介素18基因的非复制型重组鸡痘病毒活载体疫苗vUTA2-OAT以及DNA疫苗pVRI-OAT诱导FMDV模型动物豚鼠产生特异性体液免疫和细胞免疫的能力。方法将上述2种重组疫苗分别单独或联合接种豚鼠,然后测定FMDV特异性结合抗体、中和抗体和T淋巴细胞增殖反应,并用250ID50的FMDV进行攻击,观察其保护效果。结果这2种重组疫苗均能诱导豚鼠产生特异性的体液免疫及细胞免疫应答。其中以pVRI-OAT/vUTA2-OAT的联合免疫方式的效果最好,其诱导的抗体水平接近于常规灭活疫苗,而细胞免疫水平则比后者高得多。攻击保护结果显示3个重组疫苗组均有一定保护效果,完全保护率和部分保护率分别为1/4和2/4。而PBS对照组发病率为4/4。结论证实了这2种重组疫苗在豚鼠体内具有良好的免疫原性。上述研究结果为FMDV基因工程疫苗的研究奠定了基础。

腺病毒介导p21基因转染抑制人血管平滑肌细胞增殖的研究

目的 研究抗增殖性p21基因转染对体外培养的人血管平滑肌细胞(HVSMC)的增殖抑制作用及其作用机制。方法 通过腺病毒介导将外源性p21基因转入HVSMC,通过免疫印迹法(Western blot)检测p21基因的表达,原位末端标记法(TUNEL)、DNA片段梯度分析及流式细胞分析(FCM)观察靶细胞的细胞周期变化及凋亡,利用酶联免疫光度仪分析靶细胞的增殖抑制情况。结果 Western blot结果显示p21基因转染后的HVSMC可高水平表达p21蛋白,而另两组无表达。感染后5 d,Adp21组的细胞数为0.275 5±0.01(525 nm波长下吸光度A值),AdlacZ组为0.340 9±0.02,空白组为0.347 5±0.02,Adp21组较另两组的差异有统计学意义(P<0.01)。TUNEL、DNA片段梯度分析及FCM检测均提示靶细胞发生了凋亡。FCM检测还发现明显的细胞周期阻滞现象,Adp21组G0-G1期细胞比例为66.23％,S期细胞比例为10.18％,而另两组G0-G1期和S期细胞比例分别为:47.73％、30.56％和45.31％、32.34％。结论 复制缺陷性腺病毒在体外可有效介导外源性p21基因转染HVSMC,转染后的细胞除发生细胞周期阻滞外还出现明显的凋亡,其生长增殖受到抑制。

Pathogenesis of occult chronic hepatitis B virus infection

Occult hepatitis B infection(OBI) is characterized by hepatitis B virus(HBV) DNA in serum in the absence of hepatitis B surface antigen(HBsAg) presenting HBsAg-negative and anti-HBc positive serological patterns.Occult HBV status is associated in some cases with mutant viruses undetectable by HBsAg assays;but more frequently it is due to a strong suppression of viral replication and gene expression.OBI is an entity with world-wide diffusion.The failure to detect HBsAg,despite the persistence of the viral DNA,is due in most cases to the strong suppression of viral replication and gene expression that characterizes this"occult"HBV infection;although the mechanisms responsible for suppression of HBV are not well understood.The majority of OBI cases are secondary to overt HBV infection and represent a residual low viremia level suppressed by a strong immune response together with histological derangements which occurred during acute or chronic HBV infection.Much evidence suggests that it can favour the progression of liver fibrosis and the development of hepatocellular carcinoma.

儿童特发性血小板减少性紫癜病因学的初步研究

应用 Ｐ Ｃ Ｒ 和 Ｅ Ｌ Ｉ Ｓ Ａ 技术对３２ 例急性特发性血小板减少性紫癜（ Ｉ Ｔ Ｐ） 患儿的外周血进行了人细小病毒 Ｂ１９（ Ｈ Ｐ Ｖ Ｂ１９） 、 Ｅ Ｂ 病毒（ Ｅ Ｂ Ｖ） 、巨细胞病毒（ Ｃ Ｍ Ｖ） 及乙型肝炎病毒（ Ｈ Ｂ Ｖ） 系列检测。结果：病例组 Ｈ Ｐ Ｖ Ｂ１９ Ｄ Ｎ Ａ 阳性８ 例（２５ ．０ ％ ） ，与正常对照组比较有显著性差异（ Ｐ＜ ０ ．０５） 。 Ｅ Ｂ Ｖ Ｄ Ｎ Ａ 阳性２ 例， Ｃ Ｍ Ｖ Ｄ Ｎ Ａ 阳性３ 例， Ｈ Ｂｓ Ａｇ 和 Ｈ Ｂｅ Ａｇ 同时阳性２ 例，４种病毒的总阳性率为４６ ．９ ％ （１５／３２ 例） 。提示：近半数儿童 Ｉ Ｔ Ｐ 病例的发生可能与上述病毒感染有关，而 Ｈ Ｐ Ｖ Ｂ１９ 较其他病毒与 Ｉ Ｔ Ｐ 的关系更为密切。

Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece

AIM:To assess the hepatitis B virus(HBV)-DNA and the prevalence of occult HBV infection in end-stage renal failure(ESRF)patients from Central Greece. METHODS:Sera from 366 ESRF patients attending five out of six dialysis units from Central Greece were investigated for HBV-DNA by real-time polymerase chain reaction.Only serum samples with repeatedly detectable HBV-DNA were considered positive.IgG antibodies to hepatitis C virus(anti-HCV)were tested by a third generation enzyme linked immunosorbent assay(ELISA),while IgG antibodies to hepatitis E virus (anti-HEV)were tested by two commercially available ELISAs.RESULTS:HBV-DNA was detected in 15/366 patient (4.1%)and HBsAg in 20/366(5.5%).The prevalenc of occult HBV infection was 0.9%(3/346 HBsAg negative patients).Occult HBV was not associate with a specific marker of HBV infection or anti-HCV o anti-HEV reactivity.There was no significant differenc in HBV-DNA titres,demographic and biochemica features,between patients with occult HBV infectio and those with HBsAg-positive chronic HBV infection. CONCLUSION:In central Greece,4%of ESRF patient had detectable HBV-DNA,though in this setting,th prevalence of occult HBV seems to be very low(0.9%).

Serological diagnosis of Epstein-Barr virus infection: Problems and solutions

Serological tests for antibodies specific for Epstein-Barr virus(EBV) antigens are frequently used to define infection status and for the differential diagnosis of other pathogens responsible for mononucleosis syndrome. Using only three parameters [viral capsid antigen(VCA) Ig G, VCA Ig M and EBV nuclear antigen(EBNA)-1 Ig G],it is normally possible to distinguish acute from past infection: the presence of VCA Ig M and VCA Ig G without EBNA-1 Ig G indicates acute infection, whereas the presence of VCA Ig G and EBNA-1 Ig G without VCA Ig M is typical of past infection. However, serological findings may sometimes be difficult to interpret as VCA Ig G can be present without VCA Ig M or EBNA-1 Ig G in cases of acute or past infection, or all the three parameters may be detected simultaneously in the case of recent infection or during the course of reactivation. A profile of isolated EBNA-1 Ig G may also create some doubts. In order to interpret these patterns correctly, it is necessary to determine Ig G avidity, identify anti-EBV Ig G and Ig M antibodies by immunoblotting, and look for heterophile antibodies, anti-EA(D) antibodies or viral genome using molecular biology methods. These tests make it possible to define the status of the infection and solve any problems that may arise in routine laboratory practice.

阳离子膜融合脂质体包裹DNA体外转染和稳定性研究

目的 研究阳离子膜融合脂质体包裹DNA的体外稳定性以及体外细胞转染。方法 采用表达E .coilβ 半乳糖苷酶的pSV4 0 β报告基因质粒及组化染色评价阳离子膜融合脂质体的转染效率。用DNase 1考察阳离子膜融合脂质体的体外稳定性。结果 当阳离子膜融合脂质体 (CFL)及阳离子脂质体 (CL)与DNA电荷比为 (2∶1)时 ,CFL的转染效率为 (4 2 .3±4 .3) % ,明显高于CL的转染效率 (2 3.9± 2 .1) % ,且有很较高的稳定性。结论 CFL可作为载体有待进一步研究。

抗RNA病毒相关生物材料

在介绍RNA病毒结构、生殖、复制和转录的基础上 ,综述了抗病毒策略 ,其中包括抗SARS药物设计 ,RNA干扰 ,DNA疫苗释放系统 ,调控蛋白与糖胺聚糖衍生物或类似物相互作用 ,天然药物及肺泡组织工程等。这些实例涵盖了RNA病毒与蛋白质、DNA及多糖等生物材料的相互作用。生物材料作为基质或载体正在向细胞或 /和基因活化的第三代生物材料发展 。

鸡3种主要DNA病毒多重感染复合PCR检测方法的建立

依据Gen Bank中注册的鸡马立克氏病病毒(MDV)、鸡传染性喉气管炎病毒(ILTV)、鸡痘病毒(FPV)基因组核苷酸序列中的保守序列设计引物,3种病毒各设计3对引物,共计9对引物,经生物学软件筛选后,得到3对相互匹配较佳的引物。3对匹配引物经单一PCR验证后,优化复合PCR反应条件,确定最佳的退火温度、引物浓度和Taq DNA聚合酶浓度;经特异性、敏感性试验及简化PCR试验,建立简易复合PCR检测方法。复合PCR扩增出的3条带大小与预期一致,即228 bp(MDV)、400 bp(ILTV)、499 bp(FPV);建立的复合PCR方法能同时检测出100 fg MDV、ILTV、FPV的DNA。同时依据PCR技术原理,将经典的三温热循环改进为二温热循环试验,即将退火和延伸合并为一步(62℃),缩短了反应时间。建立的3种病毒的复合PCR检测方法具有较高的特异性和敏感性,可以用于临床病料的快速诊断。

Occult hepatitis B virus infection among Egyptian blood donors

AIM:To identify blood donors with occult hepatitis B virus(HBV) infection(OBI) to promote safe blood donation.METHODS:Descriptive cross sectional study was conducted on 3167 blood donors negative for hepatitis B surface antigen(HBsAg),hepatitis C antibody(HCV Ab) and human immunodeficiency virus Ab.They were subjected to the detection of alanine aminotransferase(ALT) and aspartate transaminase(AST) and screening for anti-HBV core antibodies(total) by two different techniques;[Monoliza antibodies to hepatitis B core(Anti-HBc) Plus-Bio-Rad] and(ARC-HBc total-ABBOT).Positive samples were subjected to quantitative detection of antibodies to hepatitis B surface(anti-HBs)(ETI-AB-AUK-3,Dia Sorin-Italy).Serum anti-HBs titers > 10 IU/L was considered positive.Quantitative HBV DNA by real time polymerase chain reaction(PCR)(QIAGEN-Germany) with 3.8 IU/mL detection limit was estimated for blood units with negative serum anti-HBs and also for 32 whose anti-HBs serum titers were > 1000 IU/L.Also,265 recipients were included,34 of whom were followed up for 3-6 mo.Recipients were investigated for ALT and AST,HBV serological markers:HBsAg(ETI-MAK-4,Dia Sorin-Italy),anti-HBc,quantitative detection of anti-HBs and HBV-DNA.RESULTS:525/3167(16.6%) of blood units were positive for total anti-HBc,64% of those were antiHBs positive.Confirmation by ARCHITECT anti-HBc assay were carried out for 498/525 anti-HBc positive samples,where 451(90.6%) confirmed positive.Reactivity for anti-HBc was considered confirmed only if two positive results were obtained for each sample,giving an overall prevalence of 451/3167(14.2%) for total anti-HBc.HBV DNA was quantified by real time PCR in 52/303(17.2%) of anti-HBc positive blood donors(viral load range:5 to 3.5 x 105 IU/mL) with a median of 200 IU/mL(mean:1.8 x 104 ± 5.1 x 104 IU/mL).AntiHBc was the only marker in 68.6% of donors.Univariate and multivariate logistic analysis for identifying risk factors associated with anti-HBc and HBV-DNA positivity among blood donors showed that age above thirty and marriage were the most significant risk factors for prediction of anti-HBc positivity with AOR 1.8(1.4-2.4) and 1.4(1.0-1.9) respectively.Other risk factors as gender,history of blood transfusion,diabetes mellitus,frequent injections,tattooing,previous surgery,hospitalization,Bilharziasis or positive family history of HBV or HCV infections were not found to be associated with positive anti-HBc antibodies.Among anti-HBc positive blood donors,age below thirty was the most significant risk factor for prediction of HBV-DNA positivity with AOR 3.8(1.8-7.9).According to HBV-DNA concentration,positive samples were divided in two groups;group one with HBV-DNA ≥ 200 IU/mL(n = 27) and group two with HBV-DNA < 200 IU/mL(n = 26).No significant difference was detected between both groups as regards mean age,gender,liver enzymes or HBV markers.Serological profiles of all followed up blood recipients showed that,all were negative for the studied HBV markers.Also,HBV DNA was not detected among studied recipients,none developed post-transfusion hepatitis(PTH) and the clinical outcome was good.CONCLUSION:OBI is prevalent among blood donors.Nucleic acid amplification/HBV anti core screening should be considered for high risk recipients to eliminate risk of unsafe blood donation.

福州市入境发热人群部分病毒性传染病病原谱初步研究

目的了解福州市入境发热人群病毒性传染病流行概况及病原谱构成。方法收集2009年5月-2011年5月福州市各主要口岸入境发热人群(体温≥37.5℃)的个案信息,同时采集咽拭子和/或血清标本,采用PCR和RT-PCR方法进行检测分析。结果共截获发热病人192例,采集229份标本,进行主要常见呼吸道病毒和虫媒病毒检测,共检出阳性病例39例,阳性率为20.31%(39/192);检出的病毒包括流感、副流感、呼吸道合胞、登革、偏肺和腺病毒等。结论入境人群存在携带病毒入境的可能,应加强口岸卫生检疫。